Author's response: 'Transition considerations for extended half-life factor products'.
Dana Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
S E
SE
Croteau
Dana Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.
E J
EJ
Neufeld
D001779:Blood Coagulation Factors / Q000493:pharmacokinetics*; D006801:Humans
D001779:Blood Coagulation Factors